Germany-based BioNTech got into the space before the gold rush that was unleashed in September by the news that Akeso and ...

Jemperli plus chemotherapy demonstrated superior overall survival compared to Keytruda in advanced NSCLC, with a median OS of ...

Iovance Biotherapeutics' strong Q3 earnings and promising drug pipeline suggest growth potential for risk-tolerant investors.

Australian cancer ... help. Patient groups and experts are calling on Health Minister Mark Butler to intervene and overrule ...

Welcome to the Merck & Company Q3 sales and earnings conference call. [Operator instructions] This call is being recorded.

If you have non-small cell lung cancer (NSCLC), your doctor will recommend PD-L1 testing. This test will help your doctor understand if you ... which include the following medications: pembrolizumab ...

Only some lung cancer patients benefit ... So, immunotherapy drugs help a patient’s immune system control their cancer on its own before it can spread. Unfortunately, immunotherapy does not work for ...

Brian Beers is a digital editor, writer, Emmy-nominated producer, and content expert with 15+ years of experience writing about corporate finance & accounting, fundamental analysis, and investing ...

Abravanel and his colleagues collected 67 tumour biopsies from 60 people with metastatic breast cancer, meaning it had spread to other organs, such as the liver, brain and lungs. They found that ...

Here's another good reason to help your child reach and maintain a healthy weight: A new study warns that kids who are either too skinny or too fat are at risk for impaired lung function.

Moderna and MSD have initiated a Phase III clinical study to evaluate mRNA-4157 (V940), an investigational individualised neoantigen therapy, in combination with Keytruda to treat non-small cell lung ...